|
Video: What is a Stock Split?
|
|
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Co. has a portfolio pipeline that includes several commercial products and product candidates focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. Co. has two products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD. Translarna is designed for the treatment of nonsense mutation DMD in ambulatory patients aged two years and older Emflaza is designed for the treatment of DMD in patients two years and older. According to our PTC Therapeutics stock split history records, PTC Therapeutics has had 0 splits. | |
|
PTC Therapeutics (PTCT) has 0 splits in our PTC Therapeutics stock split history database.
Looking at the PTC Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PTC Therapeutics shares, starting with a $10,000 purchase of PTCT, presented on a split-history-adjusted basis factoring in the complete PTC Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/06/2014 |
|
End date: |
05/02/2024 |
|
Start price/share: |
$17.44 |
|
End price/share: |
$33.62 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
92.78% |
|
Average Annual Total Return: |
6.79% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$19,285.36 |
|
Years: |
10.00 |
|
|
|
|
|